Frederick Hudson Biography and Net Worth

Director of Supernus Pharmaceuticals

Frederick M. Hudson has served as a member of our Board and chair of the Audit Committee since 2010. Mr. Hudson retired as a partner in the accounting firm of KPMG LLP in 2006 after a 37-year career with the firm. He was the partner in charge of the health care audit practice for the Washington-Baltimore business unit and held leadership positions within the mergers and acquisitions and venture capital services unit. Mr. Hudson currently chairs the audit committee of the board of directors of scPharmaceuticals, Inc., a publicly traded pharmaceutical company. From 2014-2019, he was a member of the Board of Directors of Aradigm Corporation and chair of the audit committee. He is a director of GBMC Healthcare, Inc. and its affiliate, Greater Baltimore Medical Center, serving as chair of the board from 2019-2022, and previously as chair of the finance committee and audit committee. Other previous directorships include: director and compliance committee member of Maxim Healthcare Services; Board of Directors member and audit committee chair of Educate, Inc., Woodhaven Holding Corp., Vicor Technologies, Inc., and Paradigm Management Services, LLC. He served on the Board of Financial Administration of the Catholic Archdiocese of Baltimore and on the Board of Trustees of the Maryland Historical Society. Mr. Hudson received a B.S. in Accounting from Loyola University Maryland and is a Certified Public Accountant (retired). Mr. Hudson’s extensive accounting and health care audit experiences qualify him to serve as a director.

What is Frederick M. Hudson's net worth?: The estimated net worth of Frederick M. Hudson is at least $2.09 million as of August 14th, 2025. Mr. Hudson owns 46,307 shares of Supernus Pharmaceuticals stock worth more than $2,088,446 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Hudson may own. Learn More about Frederick M. Hudson's net worth.
How do I contact Frederick M. Hudson?: The corporate mailing address for Mr. Hudson and other Supernus Pharmaceuticals executives is 1550 E GUDE DR, ROCKVILLE MD, 20850. Supernus Pharmaceuticals can also be reached via phone at (301) 838-2500 and via email at [email protected]. Learn More on Frederick M. Hudson's contact information.
Has Frederick M. Hudson been buying or selling shares of Supernus Pharmaceuticals?: Frederick M. Hudson has not been actively trading shares of Supernus Pharmaceuticals during the past quarter. Most recently, Frederick M. Hudson sold 7,457 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a transaction totalling $315,132.82. Following the completion of the sale, the director now directly owns 46,307 shares of the company's stock, valued at $1,956,933.82. Learn More on Frederick M. Hudson's trading history.
Who are Supernus Pharmaceuticals' active insiders?: Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Timothy Dec (CFO), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development), and Bethany Sensenig (Director). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?: In the last twelve months, insiders at the specialty pharmaceutical company sold shares 16 times. They sold a total of 373,845 shares worth more than $16,830,854.81. The most recent insider tranaction occured on October, 9th when CEO Jack A Khattar sold 59,900 shares worth more than $3,029,143.00. Insiders at Supernus Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Supernus Pharmaceuticals.
Information on this page was last updated on 10/9/2025.

Frederick M. Hudson Insider Trading History at Supernus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/14/2025	Sell	7,457	$42.26	$315,132.82	46,307
11/15/2023	Sell	9,093	$28.50	$259,150.50	33,231
7/13/2020	Sell	920	$24.44	$22,484.80

Frederick M. Hudson Buying and Selling Activity at Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Today's Range

Now: $45.10

$44.28

$45.10

50 Day Range

MA: $48.40

$44.12

$57.00

2 Week Range

Now: $45.10

$29.16

$57.65

Volume

493,657 shs

Average Volume

807,434 shs

Market Capitalization

$2.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71